PriMera Scientific Medicine and Public Health (ISSN: 2833-5627)

Review Article

Volume 4 Issue 2

Hyperlipidemia: A Review of the Innovative Approaches for the Management of Lipid

Kunika*

January 23, 2024

DOI : 10.56831/PSMPH-04-117

View PDF

Abstract

The most prevalent modifiable cause of atherosclerotic cardiovascular disease is hyperlipidemia. The notion of the inverse link between the onset of a major adverse cardiovascular event and non- high-density lipoprotein (non-HDL) and low-density lipoprotein (LDL-C) cholesterol has emerged from our understanding of controlling hyperlipidemia. An overview of lipids and their metabolism will be given in this review. It will also address hyperlipidemia and therapeutic strategies for it.

Keywords: low density lipoprotein-cholesterol; statin-induced myopathy; lipid metabolism

References

  1. Altmann SW., et al. “Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption”. Science 303 (2004): 1201-1204.
  2. Brouwers MC., et al. “The genetics of familial combined hyperlipidaemia”. Nat Rev Endocrinol 8 (2012): 352-362.
  3. Carpentier YA and Sobotka L. “Basics in clinical nutrition: lipid metabolism”. E Spen Eur E J Clin Nutr Metab 3 (2008): 4-6.
  4. Sundaram M and Yao Z. “Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion”. Nutr Metab (Lond) 7 (2010): 35.
  5. Ridker PM., et al. “HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial”. Lancet 376.9738 (2010): 333-9.
  6. Joseph D. Pharmacotherapy, A pathophysiological approach, 8thedn, The McGraw Hill companies, Inc (2011): 370.
  7. Wouters K., et al. “Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice”. Clin Chem Lab Med 43.5 (2005): 470-9.
  8. Gao W., et al. “Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease”. Lipids Health Dis 11 (2012): 55.
  9. Murphy SL, Xu J and Kochanek KD. “Deaths: final data for 2010”. Natl Vital Stat Rep 61.4 (2013): 1-117.
  10. Matthews TJ and Hamilton BE. “First births to older women continue to rise”. NCHS Data Brief 152 (2014): 1-8.
  11. Lipid Research Clinics Coronary Primary Prevention Trial. The lipid research clinics coronary primary prevention trial results. American Medical Association (1984).
  12. Manninen V., et al. “Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study”. JAMA 260.5 (1988): 641-51.
  13. Steinberg D. “Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy”. J Lipid Res 47.7 (2006): 1339-51.
  14. Steinberg D. “Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans”. J Lipid Res 46.2 (2005): 179-90.
  15. Steinberg D. “Thematic review series: the pathogenesis of atherosclerosis: an interpretive history of the cholesterol controversy, part III: mechanistically defining the role of hyperlipidemia”. J Lipid Res 46.10 (2005): 2037-51.
  16. Steinberg D. “The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part IV: the 1984 coronary primary prevention trial ends it—almost”. J Lipid Res 47.1 (2006): 1-14.
  17. Rocha VZ and Libby P. “Obesity, inflammation, and atherosclerosis”. Nat Rev Cardiol 6.6 (2009): 399-409.
  18. “National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)”. Circulation 89.3 (1994): 1333-445.
  19. Moynihan R. “Surrogates under scrutiny: fallible correlations, fatal consequences”. BMJ 343 (2011): d5160.
  20. Abourbih S., et al. “Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review”. Am J Med (2009).
  21. Jacobson TA., et al. “Fluvastatin with and without niacin for hypercholesterolemia”. Am J Cardiol 74.2 (1994): 149-54.
  22. Russell DW. “The enzymes, regulation, and genetics of bile acid synthesis”. Annu Rev Biochem 72 (2003): 137-74.
  23. Safeer RS and Lacivita CL. “Choosing drug therapy for patients with hyperlipidemia”. Am Fam Physician 61.11 (2000): 3371-82.
  24. Shattat GF. “A review article on hyperlipidemia: types, treatments and new drug targets”. Biomedical and pharmacology journal 7.1 (2015): 399-409.
  25. Singh R and Nain S. “A Mini-Review on Hyperlipidemia: Common Clinical Problem”. Interv Cardiol J 4.3 (2018): 11.